Stocks · News reference

HC Wainwright & Co. Reiterates Buy on Immunocore Holdings, Maintains $100 Price Target

Oct 26, 2026, 5:09 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

Fiscal.aiOct 29, 2026, 5:31 PM
Immunocore to Present Phase 1/2 Data for Brenetafusp and KIMMTRAK Combination at SITC 2026
Immunocore Holdings plc announced it will present clinical data from its Phase 1/2 trial evaluating brenetafusp in combination with KIMMTRAK for metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer (SITC) Annual Meeting.
IMCR
BenzingaOct 29, 2026, 1:04 PMBenzinga Newsdesk
Immunocore To Present Phase 1/2 Trial Data Evaluating Brenetafusp Alone And In Combination With KIMMTRAK In HLA-A*02:01-Positive Patients With Metastatic Uveal Melanoma, At 2026 SITC Annual Meeting
IMCR
Globenewswire IncOct 29, 2026, 1:00 PMNa
Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting
Immunocore announced it will present Phase 1 data for brenetafusp combined with KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the 2026 SITC Annual Meeting. The presentation will showcase clinical data for the first combination of two T cell engagers in a solid tumor, with poster and oral sessions scheduled for November 6-7, 2026.
IMCR